MBX Biosciences to Participate in Upcoming November Investor Conferences
Rhea-AI Summary
MBX Biosciences (NASDAQ: MBX), a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, has announced its participation in three major investor conferences in November 2024. The company will attend the Guggenheim Inaugural Healthcare Innovation Conference in Boston (Nov 12), the Stifel 2024 Healthcare Conference in New York (Nov 18), and the Jefferies London Healthcare Conference (Nov 20). Each session will feature either a fireside chat or company presentation format. Live webcasts will be available on the MBX Biosciences investor website, with replays accessible for approximately 90 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MBX declined 6.50%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences:
Guggenheim Inaugural Healthcare Innovation Conference
Date: Tuesday, November 12, 2024
Format: Fireside chat
Time: 3:30 p.m. EST
Location: Boston, MA
Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Format: Fireside chat
Time: 3:00 p.m. EST
Location: New York, NY
Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024
Format: Company presentation
Time: 3:30 p.m. GMT
Location: London, UK
Live webcasts can be accessed on the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
About MBX’s Proprietary Precision Endocrine Peptide (PEP™) Platform
MBX was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing.
Media Contact:
Kate Burdick
Inizio Evoke Comms
kate.burdick@inizioevoke.com
860-462-1569
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
What investor conferences will MBX Biosciences (NASDAQ: MBX) attend in November 2024?
How can investors access MBX Biosciences' November 2024 conference presentations?
What time is MBX Biosciences presenting at the Jefferies London Healthcare Conference 2024?
